Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.
Buzdar
A
A
Department of Breast Medical Oncology, M. D., Anderson Cancer Center, University of Texas, Houston, 77030, USA.
Howell
A
A
D000077384:Anastrozole; D000730:Androstadienes / Q000009:adverse effects / Q000627:therapeutic use; D000735:Androstenedione / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D047072:Aromatase Inhibitors; D001943:Breast Neoplasms / Q000188:drug therapy*; D004791:Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017316:Fadrozole / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D006261:Headache / Q000139:chemically induced; D006801:Humans; D000077289:Letrozole; D009325:Nausea / Q000139:chemically induced; D009570:Nitriles / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use; D014839:Vomiting / Q000139:chemically induced
D000730:Androstadienes; D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D009570:Nitriles; D014230:Triazoles; C060523:vorozole; D000077384:Anastrozole; D000735:Androstenedione; D000077289:Letrozole; D017316:Fadrozole; C056516:exemestane; C014594:formestane